Pharmaceuticals
Lilly ups stake in Chinese pharma firm
Lilly Asian Ventures, the venture capital arm of pharmaceutical giant Eli Lilly & Co., has injected an additional $20 million of capital into existing portfolio company Novast.
New Zealand’s Waterman buys 20% of Manuka Health
New Zealand-based Waterman Capital has acquired a 20% stake in natural health brand Manuka Health.
Unison secures Showa Yakuhin Kako SBO
Unison Capital has emerged victorious in the auction for Showa Yakuhin Kako, securing the secondary buyout of the drug producer from Tokio Marine Capital, Polaris Capital Group and PineBridge Investments.
Navis mulls buying Twilight Litaka stake
Malaysia-based Navis Capital Partners is in negotiations with Indian pharmaceutical company Twilight Litaka Pharma about a potential cash injection of $1.5 billion ($29 million) in the firm.
ChrysCapital reinvests $57m in Intas Pharmaceutical
ChrysCapital Partners is investing a further INR3 billion ($57 million) in Indian drugmaker Intas Pharmaceuticals ahead of the company’s upcoming initial public offering.
PAG Asia bets $250m on Chinese pharmco
China is entering a new era, with its new model for growth powered by technology and innovation rather than a focus on cheap manufacturing. Biotechnology, as one of the seven “strategic emerging industries” in the 12th Five-Year plan, is experiencing...
CDH, CITIC, New Horizon buy Luye Pharma from MBK
CDH Capital, Citic Private Equity and New Horizon Capital, three of China's largest private equity firms, have bought Luye Pharma from Korea-based MBK Partners.
PAG commits $250m to Chinese pharma company
PAG Asia has invested $250 million in Shaanxi–based Bicon Pharmaceutical Holdings, becoming its largest investor, according to a statement released by the pharma company on Tuesday.
High India pharma valuations price PE firms out of the market
With strategic investors drawn to India’s rapidly growing pharma sector, private equity players must either go niche or get out
Former ChrysCapital MD seeks $350m for new fund
Former managing director of ChrysCapital Brahmal Vasudevan is targeting $350 million for a spin out fund focusing on emerging markets in India and Southeast Asia.